| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-04-04 | XOMA 129 | severe acute hypoglycemia | preclinical | Xoma (USA - CA) | Metabolic diseases |
| 2016-04-04 | Saxenda® (liraglutide 3 mg) | treatment of adults with obesity or who are overweight with comorbidities | 3 | Novo Nordisk (Denmark) | Metabolic diseases |
| 2016-04-04 | CUDC-907 - mesylate synthetic small molecule inhibitor of HDAC and PI3K | relapsed/refractory lymphoma or multiple myeloma | 1 | Curis (USA - MA) | Cancer - Oncology |
| 2016-04-04 | CUDC-907 - mesylate synthetic small molecule inhibitor of HDAC and PI3K | relapsed and/or refractory diffuse large B-cell lymphoma | 2 | Curis (USA - MA) | Cancer - Oncology |
| 2016-04-01 | romosozumab (CDP7851/AMG 785) | postmenopausal osteoporosis | 3 | Amgen (USA - CA) UCB (Belgium) | Bone diseases |
| 2016-04-01 | galinpepimut-S (human Wilms tumor protein 1 peptides - WT1 vaccine) | acute myeloid leukemia | 1-2 | SELLAS Life Sciences (Switzerland) | Cancer - Oncology |
| 2016-04-01 | binimetinib (MEK162) | recurrent low-grade serous ovarian cancer (LGSOC) | 3 | Array BioPharma (USA) Novartis (Switzerland) | Cancer - Oncology - Rare diseases |
| 2016-03-31 | Resunab™ (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-Dibenzo(b,d)pyran-9-carboxylic acid | systemic lupus erythematosus | Corbus Pharmaceuticals (USA - MA) | Autoimmune diseases | |
| 2016-03-31 | Aplidin® (plitidepsin) in combination with dexamethasone | relapsed/refractory multiple myeloma | 3 | PharmaMar (Spain) | Cancer - Oncology - Rare diseases |
| 2016-03-30 | aramchol | NASH (non-alcoholic steatohepatitis) | preclinical | Galmed Pharmaceuticals (Israel) | Hepatic diseases - Liver diseases |
| 2016-03-30 | Docecal® (docetaxel) | Oasmia Pharmaceutical (Sweden) | Cancer - Oncology | ||
| 2016-03-29 | INO-3112 | locally advanced stage cervical cancer | 2 | Inovio Pharmaceuticals (USA - PA) European Organization for Research and Treatment of Cancer (EORTC) | Cancer - Oncology |
| 2016-03-29 | dusquetide (SGX942) | preclinical | Soligenix (USA - NJ) | Infectious diseases - Immunological diseases - Inflammatory diseases | |
| 2016-03-24 | APG101 (asunercept) | myelodysplastic syndromes (MDS) | preclinical | Apogenix (Germany) | Cancer - Oncology |
| 2016-03-24 | Cimzia® (certolizumab pegol) | rheumatoid arthritis | 4 | UCB (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-03-24 | epacadostat and CRS-207 | platinum-resistant ovarian cancer, platinum-resistant fallopian cancer, platinum-resistant peritoneal cancer, | 1-2 | Aduro Biotech (USA - CA) Incyte (USA - DE) | Cancer - Oncology |
| 2016-03-24 | Xtandi® (enzalutamide) | metastatic hormone sensitive prostate cancer (mHSPC) | 3 | Medivation (USA - CA) Astellas (Japan) | Cancer - Oncology |
| 2016-03-24 | SB8 (biosimilar version of bevacizumab - Avastin®) | non-small cell lung cancer (NSCLC) | 3 | Samsung Bioepis (Republic of Korea) | Cancer - Oncology |
| 2016-03-23 | BL-8040 | mobilization and collection of bone marrow stem cells from the peripheral blood circulation | 2 | BioLineRx (Israel) | Transplantation |
| 2016-03-23 | tasquinimod | multiple myeloma | 1 | Active Biotech (Sweden) | Cancer - Oncology |
